You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
|
|---|---|
| Published in |
International Brazilian Journal of Urology, January 2014
|
| DOI | 10.1590/s1677-5538.ibju.2014.06.16 |
| Pubmed ID | |
| Authors |
Romualdo Barroso-Sousa, Rodrigo R. Munhoz, Milena P. Mak, Leonardo G. Fonseca, Angelo B. S. Fede, Rudinei Diogo Marques Linck, Clovis R. Coelho, Camila M. V. Moniz, Ciro E. Souza, Carlos Dzik |
| Abstract |
Purpose: To assess the activity, safety and treatment patterns of sunitinib in patients with poor-risk metastatic renal cell carcinoma (mRCC). Materials and Methods: We retrospectively reviewed the charts of poor risk patients treated with sunitinib from October 2006 to July 2013 who met the eligibility criteria. The primary endpoint was overall survival (OS). Tumor radiological response was measured according to RECIST 1.1 and adverse events (AEs) were assessed through standard criteria. Results: Median OS was 8.16 months (95% CI, 5.73-10.59). Of the 53 patients included in this analysis, 9 (17.0%) achieved partial response, 12 (22.6%) had stable disease. Median treatment duration was 3.30 months (95% CI: 1.96-4.63) and 26.4% of patients discontinued treatment due to toxicity. Grade 3 or higher AEs occurred in 39.6% of patients, the most common being fatigue (15.1%), neutropenia (9.5%), nausea, vomiting and diarrhea (7.5% each). Discussion: Sunitinib may benefit some unselected poor-risk patients, although the rates of AEs and drug discontinuation suggest a need for careful patient monitoring. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 26% |
| Student > Bachelor | 3 | 16% |
| Other | 1 | 5% |
| Student > Ph. D. Student | 1 | 5% |
| Lecturer | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 6 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 11% |
| Nursing and Health Professions | 2 | 11% |
| Arts and Humanities | 1 | 5% |
| Unknown | 8 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2015.
All research outputs
#19,918,696
of 25,374,917 outputs
Outputs from International Brazilian Journal of Urology
#449
of 726 outputs
Outputs of similar age
#233,332
of 319,280 outputs
Outputs of similar age from International Brazilian Journal of Urology
#13
of 16 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 726 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,280 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.